{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:14:25Z","timestamp":1793391265225,"version":"4.5.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,5,30]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>An endogenous, dysfunctional (CRM+) FIX molecule affects prophylactic FIX efficacy. Recovery studies indicate the amount of extravascular, Col4-bound FIX is several fold greater than the FIX in plasma.<\/jats:p>","DOI":"10.1182\/blood.2018884015","type":"journal-article","created":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T03:26:36Z","timestamp":1555471596000},"page":"2445-2451","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":28,"title":["Dysfunctional endogenous FIX impairs prophylaxis in a mouse hemophilia B model"],"prefix":"10.1182","volume":"133","author":[{"given":"Brian","family":"Cooley","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"George J.","family":"Broze","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medicine, Washington University in St. Louis, St. Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Mann","sequence":"additional","affiliation":[{"name":"Mann BioConsulting, Gaithersburg, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Chang","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Biostatistics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee G.","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Department of Chemistry, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrel W.","family":"Stafford","sequence":"additional","affiliation":[{"name":"Department of Biology and Pathology, University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2019111520102219800_B1","doi-asserted-by":"crossref","first-page":"6717","DOI":"10.1016\/S0021-9258(18)88838-X","article-title":"The binding of factor IXa to cultured bovine aortic endothelial cells. Induction of a specific site in the presence of factors VIII and X","volume":"260","author":"Stern","year":"1985","journal-title":"J Biol Chem"},{"issue":"13","key":"2019111520102219800_B2","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1073\/pnas.80.13.4119","article-title":"Binding of factors IX and IXa to cultured vascular endothelial cells","volume":"80","author":"Stern","year":"1983","journal-title":"Proc Natl Acad Sci USA"},{"issue":"20","key":"2019111520102219800_B3","doi-asserted-by":"crossref","first-page":"11068","DOI":"10.1073\/pnas.93.20.11068","article-title":"Identification of the endothelial cell binding site for factor IX","volume":"93","author":"Cheung","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2019111520102219800_B4","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/jemt.20564","article-title":"Mammalian collagen IV","volume":"71","author":"Khoshnoodi","year":"2008","journal-title":"Microsc Res Tech"},{"issue":"2","key":"2019111520102219800_B5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2141.1987.tb01303.x","article-title":"In vivo evidence of intravascular binding sites for coagulation factor IX","volume":"66","author":"Stern","year":"1987","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111520102219800_B6","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1182\/blood-2004-01-0138","article-title":"Creation of a mouse expressing defective human factor IX","volume":"104","author":"Jin","year":"2004","journal-title":"Blood"},{"issue":"3","key":"2019111520102219800_B7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1055\/s-0037-1613022","article-title":"Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study","volume":"87","author":"Poon","year":"2002","journal-title":"Thromb Haemost"},{"issue":"6","key":"2019111520102219800_B8","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1021\/bi00121a031","article-title":"The endothelial cell binding determinant of human factor IX resides in the gamma-carboxyglutamic acid domain","volume":"31","author":"Toomey","year":"1992","journal-title":"Biochemistry"},{"issue":"29","key":"2019111520102219800_B9","doi-asserted-by":"crossref","first-page":"20529","DOI":"10.1016\/S0021-9258(19)36713-4","article-title":"The binding of human factor IX to endothelial cells is mediated by residues 3-11","volume":"267","author":"Cheung","year":"1992","journal-title":"J Biol Chem"},{"issue":"1","key":"2019111520102219800_B10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1182\/blood.V100.1.153","article-title":"Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo","volume":"100","author":"Gui","year":"2002","journal-title":"Blood"},{"issue":"12","key":"2019111520102219800_B11","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1111\/jth.12421","article-title":"Evidence of clinically significant extravascular stores of factor IX","volume":"11","author":"Feng","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019111520102219800_B12","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood-2016-01-696104","article-title":"Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice","volume":"128","author":"Cooley","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2019111520102219800_B13","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/j.1538-7836.2009.03545.x","article-title":"Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV","volume":"7","author":"Gui","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2019111520102219800_B14","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2141.2007.06657.x","article-title":"Inhibitor development in haemophilia B: an orphan disease in need of attention","volume":"138","author":"DiMichele","year":"2007","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111520102219800_B15","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/jth.12276","article-title":"An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B","volume":"11","author":"Rallapalli","year":"2013","journal-title":"J Thromb Haemost"},{"key":"2019111520102219800_B16","author":"Briet","year":"1977"},{"issue":"13","key":"2019111520102219800_B17","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1182\/blood.V98.13.3600","article-title":"Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates","volume":"98","author":"Roth","year":"2001","journal-title":"Blood"},{"issue":"2","key":"2019111520102219800_B18","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1046\/j.1537-2995.2002.00039.x","article-title":"Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B","volume":"42","author":"Ewenstein","year":"2002","journal-title":"Transfusion"},{"issue":"10","key":"2019111520102219800_B19","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1182\/blood.V90.10.3962","article-title":"A coagulation factor IX-deficient mouse model for human hemophilia B","volume":"90","author":"Lin","year":"1997","journal-title":"Blood"},{"issue":"23","key":"2019111520102219800_B20","doi-asserted-by":"crossref","first-page":"15213","DOI":"10.1016\/S0021-9258(18)98605-9","article-title":"Expression and characterization of human factor IX. Factor IXthr-397 and factor IXval-397","volume":"266","author":"Hamaguchi","year":"1991","journal-title":"J Biol Chem"},{"issue":"4","key":"2019111520102219800_B21","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1152\/japplphysiol.01068.2011","article-title":"Measurement of plasma volume using fluorescent silica-based nanoparticles","volume":"112","author":"Eisner","year":"2012","journal-title":"J Appl Physiol (1985)"},{"issue":"2","key":"2019111520102219800_B22","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0003-2697(92)90356-C","article-title":"Why, when, and how biochemists should use least squares","volume":"206","author":"Johnson","year":"1992","journal-title":"Anal Biochem"},{"issue":"5","key":"2019111520102219800_B23","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1365-2516.2012.02780.x","article-title":"A sensitive venous bleeding model in haemophilia A mice: effects of two recombinant FVIII products (N8 and Advate(\u00ae))","volume":"18","author":"Pastoft","year":"2012","journal-title":"Haemophilia"},{"issue":"9","key":"2019111520102219800_B24","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F","article-title":"Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians","volume":"19","author":"Carpenter","year":"2000","journal-title":"Stat Med"},{"issue":"23","key":"2019111520102219800_B25","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1091\/mbc.e10-08-0683","article-title":"A guide to simple and informative binding assays","volume":"21","author":"Pollard","year":"2010","journal-title":"Mol Biol Cell"},{"issue":"24","key":"2019111520102219800_B26","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","article-title":"Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B","volume":"369","author":"Powell","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111520102219800_B27","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/hae.12721","article-title":"Results of a phase I\/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients","volume":"21","author":"Martinowitz","year":"2015","journal-title":"Haemophilia"},{"issue":"1","key":"2019111520102219800_B28","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1073\/pnas.1307597111","article-title":"Biological role of prolyl 3-hydroxylation in type IV collagen","volume":"111","author":"Pokidysheva","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"13","key":"2019111520102219800_B29","doi-asserted-by":"crossref","first-page":"8613","DOI":"10.1074\/jbc.M114.634915","article-title":"Post-translationally abnormal collagens of prolyl 3-hydroxylase-2 null mice offer a pathobiological mechanism for the high myopia linked to human LEPREL1 mutations","volume":"290","author":"Hudson","year":"2015","journal-title":"J Biol Chem"},{"issue":"6","key":"2019111520102219800_B30","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1161\/ATVBAHA.111.225334","article-title":"In vivo fluorescence imaging of large-vessel thrombosis in mice","volume":"31","author":"Cooley","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"26","key":"2019111520102219800_B31","doi-asserted-by":"crossref","first-page":"8449","DOI":"10.1021\/bi00026a028","article-title":"Transfer of specific endothelial cell-binding properties from the procoagulant protein human factor IX into the anticoagulant protein human protein C","volume":"34","author":"Geng","year":"1995","journal-title":"Biochemistry"},{"issue":"10","key":"2019111520102219800_B32","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1182\/blood-2009-08-239665","article-title":"Prolonged activity of factor IX as a monomeric Fc fusion protein","volume":"115","author":"Peters","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2019111520102219800_B33","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF00194400","article-title":"Pharmacokinetics of factor IX in patients with haemophilia B. Methodological aspects and physiological interpretation","volume":"46","author":"Bj\u00f6rkman","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"issue":"22","key":"2019111520102219800_B34","doi-asserted-by":"crossref","first-page":"8943","DOI":"10.1073\/pnas.1014501108","article-title":"Deep-tissue anatomical imaging of mice using carbon nanotube fluorophores in the second near-infrared window","volume":"108","author":"Welsher","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2019111520102219800_B35","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/hae.12878","article-title":"Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B","volume":"22","author":"Kavakli","year":"2016","journal-title":"Haemophilia"},{"issue":"14","key":"2019111520102219800_B36","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/blood-2014-11-610824","article-title":"Crucial role for the VWF A1 domain in binding to type IV collagen","volume":"125","author":"Flood","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2019111520102219800_B37","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/jth.14341","article-title":"Defective collagen binding and increased bleeding in a murine model of von Willebrand disease affecting collagen IV binding","volume":"17","author":"Slobodianuk","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"19","key":"2019111520102219800_B38","doi-asserted-by":"crossref","first-page":"16302","DOI":"10.1074\/jbc.M011680200","article-title":"Factor IXa:factor VIIIa interaction. helix 330-338 of factor ixa interacts with residues 558-565 and spatially adjacent regions of the a2 subunit of factor VIIIa","volume":"276","author":"Bajaj","year":"2001","journal-title":"J Biol Chem"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/133\/22\/2445\/1500120\/blood884015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/133\/22\/2445\/1500120\/blood884015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T03:27:29Z","timestamp":1663298849000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/133\/22\/2445\/273873\/Dysfunctional-endogenous-FIX-impairs-prophylaxis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,30]]},"references-count":38,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2019,5,30]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2018884015","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,30]]}}}